BSE Live
Apr 02, 16:01Prev. Close
73.11
Open Price
74.92
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 02, 15:53Prev. Close
72.98
Open Price
72.00
Bid Price (Qty.)
73.81 (1)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Anuh Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 5.71 | 9.33 | 6.59 | 8.00 | 10.30 | |
| Diluted EPS (Rs.) | 5.71 | 9.33 | 6.59 | 8.00 | 10.30 | |
| Cash EPS (Rs.) | 8.52 | 9.99 | 7.32 | 8.79 | 11.20 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 64.74 | 65.69 | 59.71 | 56.09 | 47.60 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 64.74 | 65.69 | 59.71 | 56.09 | 47.60 | |
| Dividend / Share(Rs.) | 2.75 | 2.75 | 2.75 | 2.50 | 2.50 | |
| Revenue from Operations/Share (Rs.) | 122.51 | 127.98 | 95.02 | 82.27 | 130.20 | |
| PBDIT/Share (Rs.) | 10.77 | 13.66 | 10.09 | 11.81 | 16.06 | |
| PBIT/Share (Rs.) | 7.96 | 13.00 | 9.36 | 11.03 | 15.16 | |
| PBT/Share (Rs.) | 7.65 | 12.93 | 9.35 | 11.01 | 15.14 | |
| Net Profit/Share (Rs.) | 5.71 | 9.33 | 6.59 | 8.00 | 10.30 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 8.78 | 10.67 | 10.62 | 14.35 | 12.33 | |
| PBIT Margin (%) | 6.49 | 10.15 | 9.85 | 13.40 | 11.64 | |
| PBT Margin (%) | 6.24 | 10.10 | 9.83 | 13.38 | 11.62 | |
| Net Profit Margin (%) | 4.66 | 7.28 | 6.93 | 9.72 | 7.91 | |
| Return on Networth / Equity (%) | 8.81 | 14.19 | 11.03 | 14.26 | 21.63 | |
| Return on Capital Employed (%) | 12.18 | 19.68 | 15.57 | 19.55 | 21.49 | |
| Return on Assets (%) | 4.38 | 9.72 | 7.89 | 10.62 | 13.40 | |
| Total Debt/Equity (X) | 0.27 | 0.03 | 0.02 | 0.00 | 0.02 | |
| Asset Turnover Ratio (%) | 94.05 | 133.45 | 113.80 | 109.24 | 169.42 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.37 | 2.03 | 2.63 | 2.91 | 2.08 | |
| Quick Ratio (X) | 0.99 | 1.46 | 2.09 | 2.28 | 1.76 | |
| Inventory Turnover Ratio (X) | 4.99 | 7.48 | 7.46 | 6.91 | 13.77 | |
| Dividend Payout Ratio (NP) (%) | 96.33 | 29.48 | 37.93 | 6.24 | 24.27 | |
| Dividend Payout Ratio (CP) (%) | 64.58 | 27.53 | 34.14 | 5.69 | 22.32 | |
| Earnings Retention Ratio (%) | 3.67 | 70.52 | 62.07 | 93.76 | 75.73 | |
| Cash Earnings Retention Ratio (%) | 35.42 | 72.47 | 65.86 | 94.31 | 77.68 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 334.07 | 331.66 | 386.69 | 497.99 | 482.83 | |
| EV/Net Operating Revenue (X) | 1.09 | 1.03 | 1.62 | 2.42 | 1.48 | |
| EV/EBITDA (X) | 12.38 | 9.69 | 15.29 | 16.83 | 12.00 | |
| MarketCap/Net Operating Revenue (X) | 0.95 | 1.06 | 1.65 | 2.45 | 1.51 | |
| Retention Ratios (%) | 3.66 | 70.51 | 62.06 | 93.75 | 75.72 | |
| Price/BV (X) | 1.80 | 2.06 | 2.62 | 3.59 | 4.14 | |
| Price/Net Operating Revenue | 0.95 | 1.06 | 1.65 | 2.45 | 1.51 | |
| Earnings Yield | 0.05 | 0.07 | 0.04 | 0.04 | 0.05 |
10.02.2026
Anuh Pharma Standalone December 2025 Net Sales at Rs 197.18 crore, up 23.61% Y-o-Y
12.11.2025
Anuh Pharma Standalone September 2025 Net Sales at Rs 185.88 crore, up 12.01% Y-o-Y
22.08.2025
Anuh Pharma Standalone June 2025 Net Sales at Rs 186.48 crore, up 35.22% Y-o-Y
27.05.2025
Anuh Pharma Standalone March 2025 Net Sales at Rs 198.14 crore, up 20.9% Y-o-Y
10.02.2026
Anuh Pharma Standalone December 2025 Net Sales at Rs 197.18 crore, up 23.61% Y-o-Y
12.11.2025
Anuh Pharma Standalone September 2025 Net Sales at Rs 185.88 crore, up 12.01% Y-o-Y
22.08.2025
Anuh Pharma Standalone June 2025 Net Sales at Rs 186.48 crore, up 35.22% Y-o-Y
27.05.2025
Anuh Pharma Standalone March 2025 Net Sales at Rs 198.14 crore, up 20.9% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth